Kathleen A Fairman

Learn More
BACKGROUND For patients with multiple sclerosis (MS), previous research identified key disease sequelae as important cost drivers and suggested that among users of disease-modifying drugs (DMDs) in 2004, DMDs represented 73% of the total cost of care. More recent studies were limited to incident disease/treatment and/or excluded DMDs from cost estimates. To(More)
T ell the patient that the pill contains nothing but sugar, and there is no pain relief; tell him (falsely) that it contains a powerful analgesic, and the perceived level of pain falls. [Defendants insist that a] product that confers this benefit cannot be excluded from the market … just because they told the lies necessary to bring the effect about … [But](More)
  • 1